However, a study involving the analysis of long‐term phase I–III clinical trials on patients with psoriasis indicated that the IL‐23 inhibitor risankizumab did not increase the risk of malignancies over those already associated with the pathophysiology of psoriasis.12 Here, IL23A is linked to psoriasis.